ARCT लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

खरीदें 113157 min ago

@ $38.32

जारी किया गया: 15 Feb 2024 @ 01:38

वापसी: -30.79%

पिछला सिग्नल: Feb 14 - 02:18

पिछला सिग्नल: बेचें

वापसी: -0.52 %

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 01:30):

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States...

Stats
आज की मात्रा	692 569
औसत मात्रा	501 903
बाजार मूल्य	713.79M
EPS	$0 ( 2024-03-07 )
अगली कमाई की तारीख	( $-1.170 ) 2024-05-08
Last Dividend	$0.0596 ( 2013-01-08 )
Next Dividend	$0 ( N/A )
P/E	-23.68
ATR14	$0.0460 (0.17%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-25	Chivukula Pad	Sell	17 435	Common Stock
2024-03-19	Chivukula Pad	Sell	8 565	Common Stock
2023-12-15	Sassine Andy	Buy	75 000	Employee Stock Option (right to buy)
2023-12-15	Chivukula Pad	Buy	125 000	Employee Stock Option (right to buy)
2023-12-15	Kurata Lance	Buy	75 000	Employee Stock Option (right to buy)

INSIDER POWER
77.94
Last 97 transactions
Buy: 2 555 134 \| Sell: 1 046 972

मात्रा सहसंबंध

लंबा: 0.15 (neutral)

छोटा: -0.49 (neutral)

Signal:(63.822) Neutral

Arcturus Therapeutics सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध
AVEO	0.955
ITMR	0.949
RBNC	0.939
HEAR	0.932
SUMR	0.929
FCBP	0.92
DVCR	0.92
RMRM	0.918
EA	0.917
AMYT	0.917

10 सबसे अधिक नकारात्मक सहसंबंध
SBNY	-0.929
IMV	-0.925
DPRO	-0.92
NDRA	-0.913
MNDO	-0.91
CLDX	-0.909
SSPK	-0.909
WABC	-0.908
DFFN	-0.907
TCBC	-0.907

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Arcturus Therapeutics सहसंबंध - मुद्रा/वस्त्र

-0.14
( neutral )

-0.18
( neutral )

0.00
( neutral )

-0.26
( neutral )

-0.42
( neutral )

-0.15
( neutral )

Arcturus Therapeutics वित्तीय

Annual	2023
राजस्व:	$157.75M
सकल लाभ:	$154.79M (98.13 %)
EPS:	$-1.120

FY	2023
राजस्व:	$157.75M
सकल लाभ:	$154.79M (98.13 %)
EPS:	$-1.120

FY	2022
राजस्व:	$205.76M
सकल लाभ:	$62.70M (30.48 %)
EPS:	$0.350

FY	2021
राजस्व:	$12.36M
सकल लाभ:	$0.00 (0.00 %)
EPS:	$-7.74

Financial Reports:

No articles found.

Arcturus Therapeutics Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Arcturus Therapeutics Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 1.571 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$0.0200	2012-03-06
Last Dividend	$0.0596	2013-01-08
Next Dividend	$0	N/A
Payout Date	2013-01-15
Next Payout Date	N/A
# dividends	12	--
Total Paid Out	$0.679	--
Avg. Dividend % Per Year	0.00%	--
Score	2.12	--
Div. Sustainability Score	1.571
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-06-18)

$0 Estimate 0.00 %

Dividend Stability

0.02 Very Bad

Dividend Score

2.12

Pay Frequency

Monthly

Yearly Payout

Year	Amount	Yield
2012	$0	0.00%
2013	$0.119	0.23%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.165	1.500	-3.31	-4.96	[0 - 0.5]
returnOnAssetsTTM	-0.0619	1.200	-2.06	-2.48	[0 - 0.3]
returnOnEquityTTM	-0.0907	1.500	-2.12	-3.18	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	4.72	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	4.62	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	4.23	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.0704	-1.500	8.83	-10.00	[0 - 0.6]
interestCoverageTTM	-92.63	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.677	2.00	-0.226	-0.451	[0 - 30]
freeCashFlowPerShareTTM	-0.784	2.00	-0.392	-0.784	[0 - 20]
debtEquityRatioTTM	0.108	-1.500	9.57	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.341	1.000	7.65	7.65	[0.2 - 0.8]
operatingProfitMarginTTM	-0.442	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.596	1.000	-4.42	-4.42	[0.2 - 2]
assetTurnoverTTM	0.375	0.800	-0.836	-0.668	[0.5 - 2]
Total Score				1.571

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-26.56	1.000	-2.78	0	[1 - 100]
returnOnEquityTTM	-0.0907	2.50	-1.362	-3.18	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.784	2.00	-0.261	-0.784	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.677	2.00	-0.226	-0.451	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.443	1.500	-6.29	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.112	1.000	-5.30	0	[0.1 - 0.5]
Total Score				-2.19

Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.

के लिए वास्तविक समय के अद्यतन Arcturus Therapeutics [ARCT]

Upcoming Earnings Alert

Arcturus Therapeutics Dividend Information - Ex Dividend Junior

Dividend Commentary

Top 10 dividend Companies for NASDAQ

Dividend Sustainability Score (DSS)

Dividend Growth Score (DGS)